Skip to content

Annexon ANNX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.58B+197%
Omeros logo
OmerosOMER
$793.58M+8.8%
Vor Biopharma logo
Vor BiopharmaVOR
$1.22B+120%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1B+3.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.38B+19.6%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's additional paid-in capital?
Annexon (ANNX) reported additional paid-in capital of $1.17B in Q1 2026.
How has Annexon's additional paid-in capital changed year-over-year?
Annexon's additional paid-in capital increased by 15.6% year-over-year, from $1.01B to $1.17B.
What is the long-term trend for Annexon's additional paid-in capital?
Over 5 years (2020 to 2025), Annexon's additional paid-in capital has grown at a 17.2% compound annual growth rate (CAGR), from $510.31M to $1.13B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.